28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
The MAXCOG intervention is effective in improving goal performance and satisfaction in clients with MCI and early dementia. 2 key findings →
Design: randomized controlled trial Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Physical and cognitive exercise may prevent or delay dementia in later life but the neural mechanisms underlying these therapeutic benefits are largely unknown. 3 key findings →
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Care quality has important implications for people with dementia. 1 key finding →
Design: cohort study Participants: 373,695 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
If a substantial synergetic effect is detected, it may lead to the use of more widespread concurrent physical and cognitive training and the potential development of methods to make concurrent training practical. 4 key findings →
Design: randomized controlled trial Participants: 126 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our review identified several measures of speech which may assist with diagnosis and classification, and consolidated the brain-behavior associations relating to speech in FTD, PPA, and progressive apraxia of speech. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Data from 1,272,495 individuals, with the mean age at diagnosis ranging from 76.8 years (South Korea) to 82.9 years (Germany), show that the overall median length of survival following recorded diagnosis ranges from 2.4 years (New Zealand) to 7.9 years (South Korea). 2 key findings →
Design: cohort study Participants: 1,272,495 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Type 2 diabetes and cognitive dysfunction are highly prevalent disorders worldwide. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this multi-cohort study of older adults without cognitive impairment, we show that WMH and lacunes independently predict increased risk of MCR, after adjusting for key confounders. 5 key findings →
Design: cohort study Participants: 1,772 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Guidelines recommend limiting antipsychotic treatment to short-term use ( Methods Using UK primary care data from the Clinical Practice Research Datalink, linked with hospital and mortality data from Jan 1, 1998, to March 31, 2021, we emulated two sets of target trials, one after 12 weeks of antipsychotic treatment and another after 24 weeks of antipsychotic treatment, to compare continuing treatment versus tapering treatment and continuing treatment versus abrupt discontinuation of treatment. 3 key findings →
Design: cohort Participants: 24,822 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Progressive supranuclear palsy (PSP) is a clinical syndrome comprising supranuclear palsy, postural instability, and mild dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recently, there has been growing interest in the glymphatic system (the functional waste clearance pathway for the central nervous system and its role in flushing solutes (such as amyloid ß and tau), metabolic, and other cellular waste products in the brain. 4 key findings →
Participants: 36 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Adherence to the Mediterranean-DASH for Neurodegenerative Delay (MIND) diet has previously been associated with cognitive decline and dementia. 4 key findings →
Participants: 1,584 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Public health guidelines recommend exercise as a key lifestyle intervention for promoting and maintaining healthy sleep function and reducing disease risk. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Population health research is increasingly focused on the genetic determinants of healthy ageing, but there is no public resource of whole genome sequences and phenotype data from healthy elderly individuals. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Across imputed data sets, a median of 2,777 eligible individuals were included, with a median of 664 receiving a new HA prescription. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Lifestyle behavioral change is a critical component for secondary prevention of stroke. 1 key finding →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
9118 references were identified, and 103 articles (from 78 studies) published between 1992 and 2024 were included. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The clinical syndrome of pure akinesia has most often been associated with progressive supranuclear palsy (PSP) and is characterized by difficulty initiating gait and "freezing" during walking, writing and speaking. 1 key finding →
Participants: 749 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Despite a common misconception, older adults engage in sexual behavior. 4 key findings →
Design: cross-sectional Participants: 858 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
At baseline, there were 126 participants (106 [84.1%] women); mean (SD) age was 44.13 (12.71) years, mean years of interpreting experience was 8.57 (8.48) years, and 106 of 120 (88.3%) lived in an urban area. 5 key findings →
Participants: 126 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
For non-Indigenous peoples, the crude and age-standardised (World Health Organization standard) prevalence of dementia was 10.6 and 7.4 per 1000 persons, respectively. 5 key findings →
Design: cross-sectional Participants: 1,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study included 3540 participants with RVC data and 489 with WMH data (median [IQR] age: 73.2 [71.4-76.3] and 72.5 [71.2-75.4] years; female: 52.9% and 47.6%) over a median follow-up of 7.4 [IQR 5.5-8.5] and 3.8 [IQR 2.9-5.3] years, respectively. 5 key findings →
Design: cross-sectional Participants: 3,540 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The association of testosterone concentrations with dementia risk remains uncertain. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 44 experts participated in 3 survey rounds, with 28 to 31 participants each. 5 key findings →
Participants: 31 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →